Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways

Fig. 2

a Venn diagrams of co-expressed and uniquely dysregulated genes compared to control FVB/N mice in the HR-MDS, MRP8NRASD12, and tethBCL-2 transgenic mice; b Heat map of the down- and upregulated genes performed on the Sca1+ cells of HR-MDS (n = 3) compared to control FVB/N (n = 3) mice; c Distribution in % of the significantly dysregulated genes in the KEGG David annotation pathways; d Analysis of the differentially expressed genes (i.e., upregulated in the HR-MDS transgenic mice and downregulated in the founder mice and vice versa). Genes in regular font are expressed at lower levels and genes in bold font are expressed in higher levels. Examples of microarray data are shown for each intersection; e Validation of microarray data. qRT-PCR fold change of angpt1 and abcb4 gene expression in the BM and spleen cells of a different set of HR-MDS mice

Back to article page